Tesamorelin + Ipamorelin Blend – User Manual & Dosage Protocol Guide

Tesamorelin + Ipamorelin is a dual-peptide blend studied in growth hormone (GH) axis research models.

• Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH).
• Ipamorelin is a selective growth hormone secretagogue (GHS) that acts on ghrelin receptors.

This combination is investigated for its potential synergistic effects on endogenous growth hormone stimulation in experimental settings.

Research Applications

• GH pulsatility research
• IGF-1 modulation studies
• Visceral adiposity research models
• Body composition investigations
• Recovery and performance physiology models
• Sleep architecture studies

Disclaimer: Tesamorelin and Ipamorelin are for research and experimental use only in this context. Tesamorelin has specific FDA-approved indications under medical supervision, but this blended formulation is not FDA-approved for general therapeutic use.

Lyophilized Blend

Freeze-dried combined peptide vial for reconstitution

Dual Vial Kit

Separate Tesamorelin and Ipamorelin vials

Reconstituted Solution

Injectable research preparation after dilution

Concentration ratios vary by supplier.

Tesamorelin is studied for its ability to:

• Stimulate pituitary GH release via GHRH receptor activation
• Promote pulsatile GH secretion
• Increase downstream IGF-1 signaling
• Influence visceral fat metabolism in research models

Ipamorelin is studied for its ability to:

• Selectively stimulate GH release via ghrelin receptor (GHS-R1a) activation
• Minimize cortisol and prolactin stimulation compared to earlier GHS compounds
• Support physiologic GH pulse amplification

Combined Model

The blend is investigated for potential complementary stimulation of endogenous GH through dual receptor pathways.

Effects are primarily observed in controlled and investigational protocols.

Subcutaneous (SC) Research Model

Tesamorelin

Typical range: 1–2 mg

Frequency: Once daily

Notes: Often administered in the evening

Ipamorelin

Typical range: 200–500 mcg

Frequency: 1–2 times daily

Notes: Used to enhance GH pulse response

Combined Blend Example

SC Injection

Typical range: 1–2 mg Tesamorelin + 200–500 mcg Ipamorelin

Frequency: Once daily

Scheduling often aligns with pre-sleep GH pulse models.

Human-equivalent dosing should follow structured clinical evaluation.

Initiation Phase

Duration: 1–2 weeks

Purpose: GH response and tolerance evaluation

Active Study Phase

Duration: 8–12 weeks

Purpose: IGF-1 and body composition monitoring

Extended Model

Duration: Up to 16 weeks

Purpose: Visceral adiposity outcome research

Rest Period

Duration: 2–4 weeks

Purpose: GH axis reset between cycles

Cycle duration varies based on research endpoints.

Supplies

• Sterile bacteriostatic water
• Sterile syringe
• Alcohol swabs

General Procedure

1. Clean vial stopper with alcohol.
2. Add bacteriostatic water to desired concentration.

• Example: 5 mg vial + 2 mL → 2.5 mg/mL

1. Swirl gently to dissolve (do not shake).
2. Refrigerate at 2–8°C after reconstitution.
3. Use within 2–4 weeks or per research protocol.

Avoid excessive agitation to preserve peptide integrity.

Subcutaneous Injection Model

• Common sites: abdomen, thigh
• Clean site prior to administration
• Inject slowly
• Rotate injection sites

Timing is frequently aligned with natural GH secretion patterns in research settings.

Lyophilized Powder

Storage: Cool, dry environment

Shelf life: Up to 12 months

Reconstituted Solution

Storage: Refrigerated (2–8°C)

Shelf life: 2–4 weeks

Protect From:

Light, heat, and contamination

Discard if the solution becomes cloudy or discolored.

• Research use only
• Not approved for general therapeutic application
• GH-modulating peptides may influence insulin sensitivity, fluid balance, and endocrine markers in research settings
• Possible research observations may include:
• Injection-site irritation
• Mild headache
• Transient flushing
• Temporary water retention

Monitoring of IGF-1 and metabolic markers is common in investigational protocols.

Maintain sterile technique at all times.

Keep out of reach of children.

Peptides: Tesamorelin + Ipamorelin
Category: Growth Hormone Axis Research
Delivery Model: Subcutaneous research injection
Typical Investigational Range:

• Tesamorelin: 1–2 mg daily
• Ipamorelin: 200–500 mcg 1–2x daily
  Cycle: 8–12 week research models
  Storage: Refrigerated after reconstitution